Cresco Labs Stock Gross Profit

CRLBF Stock  USD 1.09  0.06  5.22%   
Cresco Labs fundamentals help investors to digest information that contributes to Cresco Labs' financial success or failures. It also enables traders to predict the movement of Cresco OTC Stock. The fundamental analysis module provides a way to measure Cresco Labs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cresco Labs otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cresco Labs OTC Stock Gross Profit Analysis

Cresco Labs' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Cresco Labs Gross Profit

    
  429.79 M  
Most of Cresco Labs' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cresco Labs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Cresco Labs reported 429.79 M of gross profit. This is 80.84% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The gross profit for all United States stocks is 98.43% higher than that of the company.

Cresco Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cresco Labs' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cresco Labs could also be used in its relative valuation, which is a method of valuing Cresco Labs by comparing valuation metrics of similar companies.
Cresco Labs is currently under evaluation in gross profit category among its peers.

Cresco Fundamentals

About Cresco Labs Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cresco Labs's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cresco Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cresco Labs based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Cresco OTC Stock

Cresco Labs financial ratios help investors to determine whether Cresco OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cresco with respect to the benefits of owning Cresco Labs security.